Show simple item record

dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorSchiffer, Celia A.
dc.date2022-08-11T08:08:27.000
dc.date.accessioned2022-08-23T15:55:34Z
dc.date.available2022-08-23T15:55:34Z
dc.date.issued2021-03-24
dc.date.submitted2021-05-28
dc.identifier.citation<p>Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chem Rev. 2021 Mar 24;121(6):3235-3237. doi: 10.1021/acs.chemrev.1c00118. PMID: 33757288; PMCID: PMC8164520. <a href="https://doi.org/10.1021/acs.chemrev.1c00118">Link to article on publisher's site</a></p>
dc.identifier.issn0009-2665 (Linking)
dc.identifier.doi10.1021/acs.chemrev.1c00118
dc.identifier.pmid33757288
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29785
dc.description.abstractThe evolutionary pressure of survival drives the emergence of drug resistance and thereby poses a major challenge to modern medicine. Resistance threatens the longevity of drugs and restricts treatment options for patients, with high prevalence in all areas of oncology and infectious diseases. Any biological entity capable of evolving and creating diversity can develop resistance under selective pressure. This diversity can pre-exist or occur after exposure to the inhibitors. Pathogens evolve to resist antimicrobials, which include antibiotics, antivirals, antifungals, and antiprotozoals. In agriculture, resistance arises with overuse of herbicides and pesticides. In cancer, resistance emerges eventually with most treatment regimens and in infectious diseases with spread of the pathogen to large populations, which is further exacerbated with the overuse of antibiotics. The emergence and spread of drug resistance in this wide range of disease areas severely impact public health, threaten millions of people’s lives, and cause a crippling financial burden, which urges the development of new strategies to unravel and avoid drug resistance.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33757288&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164520/
dc.subjectBiochemistry
dc.subjectChemicals and Drugs
dc.subjectMedicinal Chemistry and Pharmaceutics
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectPharmacy and Pharmaceutical Sciences
dc.titleIntroduction: Drug Resistance
dc.typeEditorial
dc.source.journaltitleChemical reviews
dc.source.volume121
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1996
dc.identifier.contextkey23121694
html.description.abstract<p>The evolutionary pressure of survival drives the emergence of drug resistance and thereby poses a major challenge to modern medicine. Resistance threatens the longevity of drugs and restricts treatment options for patients, with high prevalence in all areas of oncology and infectious diseases. Any biological entity capable of evolving and creating diversity can develop resistance under selective pressure. This diversity can pre-exist or occur after exposure to the inhibitors. Pathogens evolve to resist antimicrobials, which include antibiotics, antivirals, antifungals, and antiprotozoals. In agriculture, resistance arises with overuse of herbicides and pesticides. In cancer, resistance emerges eventually with most treatment regimens and in infectious diseases with spread of the pathogen to large populations, which is further exacerbated with the overuse of antibiotics. The emergence and spread of drug resistance in this wide range of disease areas severely impact public health, threaten millions of people’s lives, and cause a crippling financial burden, which urges the development of new strategies to unravel and avoid drug resistance.</p>
dc.identifier.submissionpathfaculty_pubs/1996
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages3235-3237


This item appears in the following Collection(s)

Show simple item record